EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access

Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma

Elizabeth M Burton iD, Denái R Milton, Michael T Tetzlaff, Khalida Wani, Merrick I Ross, Michael A Postow iD, Rossana Lazcano, Isabella C Glitza iD, Michael K Wong iD, Sapna P Patel iD, Adi Diab, Jeffrey E Gershenwald iD und 16 weitere

Journal of Clinical Oncology · 10.09.2025 · 43 (26) · 2856-2862

DOI: 10.1200/jco-25-00494 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.09.2025. Verfasst von Elizabeth M Burton und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX. Hauptthemen laut MEDLINE: Nivolumab, Melanoma, Biomarkers, Tumor, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint blockade (ICB) has revolutionized outcomes for patients with melanoma across multiple disease settings. In patients with advanced, unresectable disease, the ICB combination of nivolumab (anti-PD1) and relatlimab (anti–LAG-3) has demonstrated improved clinical outcomes compared with nivolumab monotherapy. There exists an unmet need to identify biomarkers that predict response to this combination regimen and rational therapeutic strategies to overcome resistance. We previously reported the initial results of a phase II clinical trial (ClinicalTrials.gov identifier: NCT02519322 ) of neoadjuvant systemic treatment (NST) followed by adjuvant treatment with nivolumab and relatlimab, which achieved a major pathologic response (MPR; ≤10% viable tumor) rate of 63% in patients with stage III/IV, surgically resectable melanoma. Our updated clinical follow-up (median 47 months) for these patients demonstrates that at 4 years from the start of NST, 80% of patients remain event-free, including 95% of patients who achieved a MPR. Gene expression analysis of longitudinally collected biospecimens from the trial identifies baseline upregulation of several immune modulatory pathways associated with MPR; by contrast, increased B7-H3 expression was associated with resistance. This work demonstrates the long-term benefit of neoadjuvant nivolumab and relatlimab and identifies a potentially targetable predictor of resistance to this combination therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NivolumabMelanomaBiomarkers, TumorAntineoplastic Combined Chemotherapy ProtocolsSkin NeoplasmsHumansNeoadjuvant TherapyFemaleMaleMiddle AgedLymphocyte Activation Gene 3 ProteinAgedChemotherapy, AdjuvantAdultAntibodies, Monoclonal, HumanizedImmune Checkpoint InhibitorsProgrammed Cell Death 1 Receptor

Substanzen

NivolumabBiomarkers, TumorLymphocyte Activation Gene 3 ProteinLag3 protein, humanAntibodies, Monoclonal, HumanizedImmune Checkpoint InhibitorsProgrammed Cell Death 1 Receptorrelatlimab

Autor:innen und Institutionen

  • Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Department of Pathology, The University of California San Francisco, San Francisco, CA.
  • Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY.

ORCID-Profile: Elizabeth M Burton, Michael A Postow, Isabella C Glitza, Michael K Wong, Sapna P Patel, Jeffrey E Gershenwald, Jennifer L McQuade, Allison Betof Warner, Victor G Prieto, Jeffrey E Lee, Sarah B Fisher, Addison Song, Michael A Davies, Alexander Lazar, Hussein A Tawbi

Förderung

  • NCI NIH HHS
  • NCATS NIH HHS

Zitieren

APA

Burton, E. M., Milton, D. R., Tetzlaff, M. T., Wani, K., Ross, M. I., Postow, M. A., Lazcano, R., Glitza, I. C., Wong, M. K., Patel, S. P., Diab, A., Gershenwald, J. E., McQuade, J. L., Betof Warner, A., Prieto, V. G., Lee, J. E., Goepfert, R. P., Fisher, S. B., Song, A., …, & Amaria, R. N. (2025). Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma. Journal of Clinical Oncology, 43(26), 2856-2862. https://doi.org/10.1200/jco-25-00494

Vancouver

Burton EM, Milton DR, Tetzlaff MT, Wani K, Ross MI, Postow MA, et al. Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma. Journal of Clinical Oncology. 2025;43(26):2856-2862. doi:10.1200/jco-25-00494

BibTeX
@article{Burton2025,
  author = {Burton, Elizabeth M and Milton, Denái R and Tetzlaff, Michael T and Wani, Khalida and Ross, Merrick I and Postow, Michael A and Lazcano, Rossana and Glitza, Isabella C and Wong, Michael K and Patel, Sapna P and Diab, Adi and Gershenwald, Jeffrey E and McQuade, Jennifer L and Betof Warner, Allison and Prieto, Victor G and Lee, Jeffrey E and Goepfert, Ryan P and Fisher, Sarah B and Song, Addison and Malke, Jared and Simon, Julie M and Ariyan, Charlotte and Torres-Cabala, Carlos A and Davies, Michael A and Lazar, Alexander and Wargo, Jennifer A and Tawbi, Hussein A and Amaria, Rodabe N},
  title = {Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  volume = {43},
  number = {26},
  pages = {2856--2862},
  doi = {10.1200/jco-25-00494}
}
Kostenlos starten →